A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study)

Mahiran Mustafa, Wai Ming Chan, Christopher Lee, Eddy Harijanto, Chian Min Loo, Nguyen Van Kinh, Nguyen Dat Anh, Jemelyn Garcia

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Doripenem is approved in the Asia-Pacific (APAC) region for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP), complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs). Clinical usage of doripenem (500 mg intravenously, infused over 1 h or 4 h every 8 h for 5-14 days) in APAC was evaluated in a prospective, open-label, non-comparative, multicentre study of inpatients (=18 years) with NP, VAP, cIAI or cUTI. A total of 216 [intention-to-treat (ITT)] patients received doripenem: 53 NP (24.5%); 77 VAP (35.6%); 67 cIAI (31.0%); and 19 cUTI (8.8%). Doripenem MIC90 values for Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae were 32, 32, 0.094 and 0.64 μg/mL, respectively. Doripenem was used most commonly as monotherapy (86.6%) and as second-line therapy (62.0%). The clinical cure rate in clinically evaluable patients was 86.7% at the end of therapy (EOT) and 87.1% at test of cure (TOC) (7-14 days after EOT). In the ITT population, overall clinical cure rates were 66.2% at EOT and 56.5% at TOC. The median duration of hospital stay, intensive care unit (ICU) stay and mechanical ventilation was 20, 12 and 10 days, respectively. Of 146 discharged patients, 7 were re-admitted within 28 days of EOT; 1 VAP patient was re-admitted to the ICU. The all-cause mortality rate was 22.7% (49/216). The most common treatment-related adverse events were diarrhoea (1.4%) and vomiting (1.4%). Doripenem is a viable option for treating APAC patients with NP, VAP, cIAI or cUTI. [ClinicalTrials.gov: NCT 00986102].

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalInternational Journal of Antimicrobial Agents
Volume43
Issue number4
DOIs
Publication statusPublished - Apr 2014

Keywords

  • Asia-Pacific
  • Doripenem
  • Medical resource utilisation

Fingerprint

Dive into the research topics of 'A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study)'. Together they form a unique fingerprint.

Cite this